FDA Clears First BAFF/APRIL Blocker for Kidney Disease Linked to Autoimmunity
The FDA granted accelerated approval to atacicept (Trutakna) for primary IgA nephropathy, the first therapy to block two key immune signaling proteins at once, though confirmatory...
Read More — FDA Clears First BAFF/APRIL Blocker for Kidney Disease Linked to Autoimmunity »